SKIN RESEARCH CASE STUDY
About the Study The study was a randomised, double- blinded, parallel, placebo-controlled clinical trialwithahealthyadultpopulation. The study involved visits over a 15-week period to complete a 12-week intervention period with collection of study objectives at participants visits. Trans-Epidermal Water Loss (skin barrier function) was assessed using TEWAMeter®, skin hydration using Corneometer®, skin firmness using Cutometer® and Omega- 3-index using finger prick blood test. Subjects were screened to identify eligible participants. All participants were randomised. Volunteers consumed one capsule of investigational product orally each morning of the intervention period. Prior to the screening visit, participants completed the consenting process and provided informed written consent. Participants completed a screening visit to evaluate their eligibility for the study, and if the participant met all eligibility requirements, they were scheduled for the next visit. At further visits, participants were assessed for eligibility and if all
DESIGN
ETHICS
RECRUITMENT
CONDUCT
ANALYSIS
REPORTING
inclusion/exclusion criteria were met, baseline assessments were completed, and participants were randomised to one of two treatment groups in a ratio of 1:1. There were interesting findings regarding improvement in TEWL and Omega-3 Index blood spot levels after 12 weeks of supplementation of the investigational supplement, compared toplacebo.While therewereoutliers in thedata, this isnot unusual given the myriad of factors that can impact TEWL. Further investigation may provide further information on these significant findings.
atlantiaclinicaltrials.com
3
Powered by FlippingBook